Research and Development

Scientists have brought the prospect of spinal cord injuries being able to be treated with stem cells one step closer, …

Celgene has been dealt a heavy blow, revealing that the FDA has rejected its New Drug Application for its sphingosine …

Biotechs created from big pharma companies tend to have an easier start to life than most, and this is definitely …

Though never truly out of vogue, the drug pricing debate has flared up again with the White House’s release of …

At the start of year, Generation Bio was revealed to the public, announcing that it had been developing gene therapies …

The FDA is set to refocus its efforts in combating the United States’ opioid crisis. Speaking at a meeting of …

It’s the last Friday of February, and it’s time for another run-down of the most popular stories of the week. …

One of the key challenges facing the treatment of cancer is knowing whether a particular drug will work with an …

Novo Nordisk has lifted the curtain on much-anticipated results data from the first of ten Phase 3 trials into the …

Speaking to Pharmafocus , David Nicholson, Chief R&D Officer at Allergan, revealed that the company has big plans in the …

Reports are emerging which detail some pretty alarming side-effects in patients receiving Regeneron’s blockbuster eye drug Eylea: once injected into …

MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …

AstraZeneca continues to build on its relationship with San Diego-based Ionis Pharmaceuticals, this time by agreeing a licensing deal for …

US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial …

Sailing against the prevailing winds in the Alzheimer’s disease space, AbbVie has launched a deal worth a potential $1.1 billion …